Loading
JPXHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
¥58.00
¥0.00 · 0.00%
Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.
Latest quote
¥58.00
¥0.00 · 0.00%
Regular session · JST · Market data may be delayed.
Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.
Day range
Current ¥58.00
52-week range
Current ¥58.00
Regular session · JST · Market data may be delayed.
Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption systems. Their innovation centers on technologies such as the Ionic Liquid Transdermal System (ILTS) and the Nano-sized Colloid Transdermal System (NCTS). MedRx also actively researches the pain-free transdermal delivery of various substances, including vaccines, nucleic acid medicines, and protein medicines. Its diverse product pipeline includes MRX-4TZT, undergoing Phase I clinical trials for spastic paralysis, and MRX-9FLT, also in Phase I, designed to alleviate chronic, cancer-related, and severe pain. Additionally, MRX-7MLL for Alzheimer's disease and MRX-6LDT for chronic pain are both in pre-clinical development. A notable achievement is MRX-5LBT, which has successfully concluded clinical trials for treating postherpetic nerve pain.
Day range
Current ¥58.00
52-week range
Current ¥58.00
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 128.08M JPY | 257.92M JPY | 29.53M JPY | 59.48M JPY | 8.35M JPY |
| Cost of goods sold | 15.07M JPY | 38.73M JPY | 47.97M JPY | 49.04M JPY | 62.6M JPY |
| Gross profit | 113.01M JPY | 219.19M JPY | −18.43M JPY | 10.45M JPY | −54.25M JPY |
| Research and development | 838.82M JPY | 809.81M JPY | 694.12M JPY | 877.75M JPY | 737.13M JPY |
| Selling, general, and administrative | 216.19M JPY | 202.43M JPY | 221.02M JPY | 233.81M JPY | 269.84M JPY |
| Operating expenses | 1.06B JPY | 1.01B JPY | 915.14M JPY | 1.11B JPY | 1.01B JPY |
| Interest income | 2.5M JPY | 225K JPY | 10K JPY | 17K JPY | 13K JPY |
| Interest expense | — | — | — | — | 1.47M JPY |
| Depreciation and amortization | 13.87M JPY | 38.43M JPY | 45.57M JPY | 46.42M JPY | 60.34M JPY |
| Operating income | −942M JPY | −793.05M JPY | −933.57M JPY | −1.1B JPY | −1.06B JPY |
| Net income | −937.37M JPY | −806.76M JPY | −932.9M JPY | −1.11B JPY | −1.06B JPY |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
